While there have been improvements in therapies to treat Parkinson’s symptoms, people living with the disease and their loved ones await a treatment that will slow the progression of Parkinson’s disease (PD) or stop it entirely. These therapies, called disease-modifying therapies, have the potential to change how PD is treated and experienced. Tune into audio from this Third Thursdays Webinar to listen to our panel of experts discuss disease-modifying therapies and the latest in Parkinson’s research.
If you’d rather listen on the go, subscribe to The Michael J. Fox Foundation’s Parkinson’s Podcast on iTunes or your preferred podcast app. If you enjoyed what you heard, share it with a friend or leave a review! It helps listeners like you find and support our mission.
In this episode, Katie Kopil, PhD, senior vice president and head of clinical research at The Michael J. Fox Foundation, speaks with:
- Sarah Zenner-Dolan, a Parkinson’s advocate. She was diagnosed with PD in 2018 and serves on several committees including the Critical Path Institute Clinical Trial Endpoints Team and the U.S. Food and Drug Administration Advisory Committee.
- Ruth Schneider, MD, a movement disorder specialist, researcher and associate professor at University of Rochester Medicine.
- Jiwon Oh, MD, PhD a staff neurologist, scientist and medical director of the Barlo Multiple Sclerosis Program at St. Michael’s hospital. She is also an associate professor at the University of Toronto.
View a transcript of this podcast.
Whether you have Parkinson’s or not, you can help move research forward. Join the study that’s changing everything.
This webinar was produced with support from Biohaven.